{
    "eid": "2-s2.0-85115990967",
    "title": "Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Acute myeloid leukemia",
        "immune checkpoint",
        "programmed cell death 1",
        "programmed cell death ligand 1",
        "T cell immunoglobulin and mucin-domain containing-3"
    ],
    "authors": [
        "Thunyamon Chajuwan",
        "Patsita Kansuwan",
        "Sirorat Kobbuaklee",
        "Chantiya Chanswangphuwana"
    ],
    "citedby-count": 3,
    "ref-count": 44,
    "ref-list": [
        "Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges",
        "PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations",
        "The blockade of immune checkpoints in cancer immunotherapy",
        "The emerging role of immune checkpoint based approaches in AML and MDS",
        "Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML",
        "Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia",
        "The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia",
        "Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy",
        "Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients",
        "Increased PD-1 + tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML",
        "The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector",
        "PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model",
        "Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies",
        "Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study",
        "Tim-3 and its role in regulating anti-tumor immunity",
        "TIM3 comes of age as an inhibitory receptor",
        "Gal9/tim-3 expression level is higher in AML patients who fail chemotherapy",
        "Increasing tim-3 + CD244+, tim-3 + CD57+, and tim-3 + PD-1+ T cells in patients with acute myeloid leukemia",
        "Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification",
        "Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML",
        "Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1",
        "Differential expression and biochemical activity of the immune receptor tim-3 in healthy and malignant human myeloid cells",
        "A TIM-3/gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression",
        "The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells",
        "TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells",
        "TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells",
        "Tim-3 finds its place in the cancer immunotherapy landscape",
        "One stone, two birds: the roles of tim-3 in acute myeloid leukemia",
        "Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9",
        "Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity",
        "TIM-3 expression is downregulated on human NK cells in response to cancer targets in synergy with activation",
        "TIM-3/gal-9 interaction induces IFN\u03b3-dependent IDO1 expression in acute myeloid leukemia blast cells",
        "Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel",
        "Acute myeloid leukaemia and related precursor neoplasm",
        "TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients",
        "Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome",
        "Acute myeloid leukemia and NK cells: two warriors confront each other",
        "Increased tim-3 expression in peripheral NK cells predicts a poorer prognosis and tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma",
        "TNF-\u03b1-induced tim-3 expression marks the dysfunction of infltrating natural killer cells in human esophageal cancer",
        "Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells",
        "High tim-3 expression on AML blasts could enhance chemotherapy sensitivity",
        "Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade",
        "The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy",
        "Minimal PD-1 expression in mouse and human NK cells under diverse conditions"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Ratchadapisek Sompotch Foundation",
        "Thai Society of Hematology"
    ]
}